J&J’s Darzalex Scores Again In Frontline Myeloma

But Challenger Arriving In 2020

 
• By Andrew McConaghie

Janssen’s hemato-oncology success rolls on with impressive new overall survival data

Johnson_and_Johnson
CAR-T candidate JNJ-4528 is set to add to Darzalex and Imbruvica in J&J's hemato-oncology franchise

More from R&D

More from Scrip